Novo Nordisk A/S

Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

By Rebecca Robbins and Dani Blum

Drugs (Pharmaceuticals) GLP-1 RAs (Drug) Health Insurance and Managed Care Novo Nordisk A/S Prices (Fares, Fees and Rates) Weight

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

By Rebecca Robbins

Company Reports Drugs (Pharmaceuticals) GLP-1 RAs (Drug) International Trade and World Market Jorgensen, Lars Fruergaard Novo Nordisk A/S

Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

By Eshe Nelson

Drugs (Pharmaceuticals) GLP-1 RAs (Drug) Health and Human Services Department Health Insurance and Managed Care Medicare Novo Nordisk A/S Obesity Ozempic (Drug) Prices (Fares, Fees and Rates) United States Politics and Government Weight

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

By Rebecca Robbins